ANRS 0406s PrevHPV-TG : Prevalence of HPV and STI infections

Prevalence of human papillomavirus (HPV) infection and sexually transmitted infections (STI) at the genital, anal and ENT level in transgender population

Last updated on 14 February 2025

This research focuses on Human Papillomavirus (HPV) and will be carried out on transgender people, i.e. people who do not identify with the gender assigned to them at birth. HPVs are widespread viruses that affect both men and women. They are mainly transmitted through sexual intercourse.Research has shown that HPV infections are responsible for cervical cancer, anal cancer and cancers of the ENT sphere (mouth, pharynx, etc.). To date, there have been very few studies on HPV in the transgender population.

Objective: to estimate the prevalence of HPV infections in a population of transgender people.

 

The aim of this research is to assess the proportion of transgender people who have contracted an HPV infection and to analyse the location of the infection and its association with other sexually transmitted infections or associated pathologies.

The results of the research will make it possible to verify whether the types of HPV most frequently found in transgender people are indeed targeted by existing vaccines. It may also make it possible to determine whether the guidelines for screening for anal cancer lesions are adequate.

Primary endpoint:

The main outcome measure of the research is the prevalence of HPV infections in a population of transgender people. Prevalence is defined as the percentage of people with an HPV infection among the transgender people included, regardless of the site (anal, genital or ENT) where the infection was detected.

Theme
HPV, STI

Status
Ongoing inclusions

Population
Trangender population

You are participating or have participated in this study

On the form above, you will find information on the ancillary studies for which your data/samples will be or ay have been re-used if you gave your consent at the time of inclusion.

If you would like to find out more about your participation in a clinical study, please see the section below.

Visit the participant area